899 related articles for article (PubMed ID: 18397336)
21. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
[TBL] [Abstract][Full Text] [Related]
22. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
Abb J
Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
[No Abstract] [Full Text] [Related]
23. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
Luh KT; Hsueh PR; Teng LJ; Pan HJ; Chen YC; Lu JJ; Wu JJ; Ho SW
Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the MicroScan system and the agar dilution assay for Quinupristin/Dalfopristin susceptibility of Enterococcus faecium.
Kim YR; Kim SI; Hur JA; Kim YJ; Wie SH; Park YJ; Kang MW
Ann Clin Lab Sci; 2007; 37(3):260-2. PubMed ID: 17709691
[TBL] [Abstract][Full Text] [Related]
25. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.
Johnson AP; Tysall L; Stockdale MV; Woodford N; Kaufmann ME; Warner M; Livermore DM; Asboth F; Allerberger FJ
Eur J Clin Microbiol Infect Dis; 2002 Oct; 21(10):751-4. PubMed ID: 12415476
[TBL] [Abstract][Full Text] [Related]
26. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.
Swoboda S; Fritz S; Martignoni ME; Feldhues RA; Hoppe-Tichy T; Buchler MW; Geiss HK
J Antimicrob Chemother; 2005 Oct; 56(4):787-9. PubMed ID: 16143710
[TBL] [Abstract][Full Text] [Related]
27. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
[TBL] [Abstract][Full Text] [Related]
28. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
[TBL] [Abstract][Full Text] [Related]
29. Quinupristin-dalfopristin and linezolid: evidence and opinion.
Eliopoulos GM
Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
[TBL] [Abstract][Full Text] [Related]
30. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
[TBL] [Abstract][Full Text] [Related]
32. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
Weigel LM; Donlan RM; Shin DH; Jensen B; Clark NC; McDougal LK; Zhu W; Musser KA; Thompson J; Kohlerschmidt D; Dumas N; Limberger RJ; Patel JB
Antimicrob Agents Chemother; 2007 Jan; 51(1):231-8. PubMed ID: 17074796
[TBL] [Abstract][Full Text] [Related]
33. Linezolid-resistant Enterococcus faecium and Enterococcus faecalis isolated from a septic patient: report of first isolates in Germany.
Halle E; Padberg J; Rosseau S; Klare I; Werner G; Witte W
Infection; 2004 Jun; 32(3):182-3. PubMed ID: 15188081
[TBL] [Abstract][Full Text] [Related]
34. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
[TBL] [Abstract][Full Text] [Related]
35. [Activity of vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus in the period 1994-1999].
Nashev D; Toshkova K; Gavrilova V
Vutr Boles; 2000; 32(2):35-40. PubMed ID: 11227664
[TBL] [Abstract][Full Text] [Related]
36. Linezolid resistance in Enterococcus faecium isolated in Ontario, Canada.
Patel SN; Memari N; Shahinas D; Toye B; Jamieson FB; Farrell DJ
Diagn Microbiol Infect Dis; 2013 Dec; 77(4):350-3. PubMed ID: 24095643
[TBL] [Abstract][Full Text] [Related]
37. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype.
Pillai SK; Sakoulas G; Wennersten C; Eliopoulos GM; Moellering RC; Ferraro MJ; Gold HS
J Infect Dis; 2002 Dec; 186(11):1603-7. PubMed ID: 12447736
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
39. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
Rybak MJ; Hershberger E; Moldovan T; Grucz RG
Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
[TBL] [Abstract][Full Text] [Related]
40. The post-antibiotic effects of linezolid against Gram-positive pathogens.
Hosgor-Limoncu M; Ermertcan S; Tasli H; Aydemir S
Saudi Med J; 2007 Apr; 28(4):551-4. PubMed ID: 17457476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
